Dyslipidaemia clinical trials

Explore recruiting dyslipidaemia clinical trials.

Recruiting dyslipidaemia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Dyslipidaemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A phase III, double blind, randomised, two arms, parallel study to compare the efficacy and safety of a 12-week administration of two fixed-dose combinations (Rosuvastatin 20 mg and Fenofibrate 160 mg versus Pravastatin 40 mg and Fenofibrate 160 mg (Pravafenix®)) in patients with mixed dyslipidaemia.

Greece

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized, double-blind, placebo-controlled study to evaluate efficacy and safety of early in hospital initiation of inclisiran treatment in patients with acute coronary syndromes: Victorion – RIDES

Germany, Hungary, Poland, France, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multicentre controlled, randomised, single-blind adaptive phase IV protocol to evaluate efficacy, safety and cost-efficacy of pre-emptive genotyping strategy in a population at risk of cardiovascular disease susceptible of receiving high or moderate-intensity doses of statins

Spain

Therapeutic use (Phase IV) EU CTIS Study details

Bioequivalence clinical trial of two formulations of rosuvastatin.

Spain

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

Implementation Study of Lipid Management of High-risk Cardiovascular Patients- Semmelweis Lipid Center for High-risk Patients

Hungary

Therapeutic use (Phase IV) EU CTIS Study details

Long-term efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema 2.4 mg/2.4 mg) once weekly versus placebo in participants with obesity

Denmark, Belgium, Portugal

Therapeutic confirmatory (Phase III) EU CTIS Study details

Dyslipidaemia trials by city

Dyslipidaemia in Toronto Dyslipidaemia in Vancouver Dyslipidaemia in Montreal Dyslipidaemia in Calgary Dyslipidaemia in Edmonton Dyslipidaemia in Ottawa Dyslipidaemia in Winnipeg Dyslipidaemia in Quebec City Dyslipidaemia in Hamilton Dyslipidaemia in Kitchener Dyslipidaemia in London Dyslipidaemia in Halifax Dyslipidaemia in New York Dyslipidaemia in Los Angeles Dyslipidaemia in Chicago Dyslipidaemia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease